#BEGIN_DRUGCARD DB00187

# AHFS_Codes:
24:24.00

# ATC_Codes:
C07AB09

# Absorption:
Rapidly absorbed, steady-state blood levels for dosages from 50-300 &micro;g/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.

# Biotransformation:
Rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Mainly in red blood cells to a free acid metabolite (with 1/1500 the activity of esmolol) and methanol.

# Brand_Mixtures:
Not Available

# Brand_Names:
Brevibloc
Esmolol HCL
Esmolol Hydrochloride

# CAS_Registry_Number:
103598-03-4

# ChEBI_ID:
4856

# Chemical_Formula:
C16H25NO4

# Chemical_IUPAC_Name:
methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2188864

# Description:
Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.

Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

# Dosage_Forms:
Liquid	Intravenous

# Drug_Category:
Adrenergic beta-Antagonists

# Drug_Interactions:
Acetohexamide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Chlorpropamide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Clonidine	Increased hypertension when clonidine stopped
Dihydroergotamine	Ischemia with risk of gangrene
Dihydroergotoxine	Ischemia with risk of gangrene
Disopyramide	The beta-blocker, esmolol, may increase the adverse effects of disopyramide.
Epinephrine	Hypertension, then bradycardia
Ergonovine	Ischemia with risk of gangrene
Ergotamine	Ischemia with risk of gangrene
Fenoterol	Antagonism
Formoterol	Antagonism
Gliclazide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Glipizide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Glisoxepide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Glyburide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Glycodiazine	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Ibuprofen	Risk of inhibition of renal prostaglandins
Indomethacin	Risk of inhibition of renal prostaglandins
Insulin Aspart	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Insulin Detemir	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Insulin Glargine	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Insulin Glulisine	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Insulin Lispro	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Isoproterenol	Antagonism
Lidocaine	The beta-blocker, esmolol, may increase the effect and toxicity of lidocaine.
Methysergide	Ischemia with risk of gangrene
Orciprenaline	Antagonism
Pipobroman	Antagonism
Pirbuterol	Antagonism
Piroxicam	Risk of inhibition of renal prostaglandins
Prazosin	Risk of hypotension at the beginning of therapy
Procaterol	Antagonism
Repaglinide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Salbutamol	Antagonism
Salmeterol	Antagonism
Terazosin	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Terbutaline	Antagonism
Tolazamide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Tolbutamide	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Verapamil	Increased effect of both drugs

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Very soluble as hydrochloride salt

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Esmolol

# HET_ID:
Not Available

# Half_Life:
Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.

# InChI_Identifier:
InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3

# InChI_Key:
InChIKey=AQNDDEOPVVGCPG-UHFFFAOYSA-N

# Indication:
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

# KEGG_Compound_ID:
C06980

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
187

# Mechanism_Of_Action:
Similar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
295.374

# Molecular_Weight_Mono:
295.178358293

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Esmolol Pathway	SMP00301

# PharmGKB_ID:
PA449500

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.02

# Predicted_LogS:
-3.3

# Predicted_Water_Solubility:
1.44e-01 g/l

# Primary_Accession_No:
DB00187

# Protein_Binding:
55% bound to human plasma protein, while the acid metabolite is 10% bound.

# PubChem_Compound_ID:
59768

# PubChem_Substance_ID:
46506146

# RxList_Link:
http://www.rxlist.com/cgi/generic3/esmolol.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00954

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include cardiac arrest, bradycardia, hypotension, electromechanical dissociation and loss of consciousness.

# Update_Date:
2013-02-08 16:19:09 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Esmolol

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
multi-pass membrane protein. Localized at the plasma membrane. Found in the Golgi upo

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
1975995	Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA: Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg. 1990 Oct;71(4):384-8.
2568748	Kirshenbaum JM: Nonthrombolytic intervention in acute myocardial infarction. Am J Cardiol. 1989 Jul 18;64(4):25B-28B.
2894187	Jacobs JR, Maier GW, Rankin JS, Reves JG: Esmolol and left ventricular function in the awake dog. Anesthesiology. 1988 Mar;68(3):373-8.
7612051	Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D: Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung. 1995 May;45(5):536-41.
7957532	Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46(5):399-404.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRB1

# Drug_Target_1_GenBank_ID_Gene:
J03019

# Drug_Target_1_GenBank_ID_Protein:
178200

# Drug_Target_1_GeneCard_ID:
ADRB1

# Drug_Target_1_Gene_Name:
ADRB1

# Drug_Target_1_Gene_Sequence:
>1434 bp
ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTACGCGAGCAG
AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG

# Drug_Target_1_General_Function:
Involved in beta1-adrenergic receptor activity

# Drug_Target_1_General_References:
10212248	Mason DA, Moore JD, Green SA, Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999 Apr 30;274(18):12670-4.
10477438	Moore JD, Mason DA, Green SA, Hsu J, Liggett SB: Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat. 1999 Sep 19;14(3):271.
11052857	Borjesson M, Magnusson Y, Hjalmarson A, Andersson B: A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 2000 Nov;21(22):1853-8.
11854867	Ranade K, Jorgenson E, Sheu WH, Pei D, Hsiung CA, Chiang FT, Chen YD, Pratt R, Olshen RA, Curb D, Cox DR, Botstein D, Risch N: A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet. 2002 Apr;70(4):935-42. Epub 2002 Feb 18.
2825170	Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7920-4.

# Drug_Target_1_HGNC_ID:
HGNC:285

# Drug_Target_1_HPRD_ID:
00181

# Drug_Target_1_ID:
193

# Drug_Target_1_Locus:
10q24-q26

# Drug_Target_1_Molecular_Weight:
51323

# Drug_Target_1_Name:
Beta-1 adrenergic receptor

# Drug_Target_1_Number_of_Residues:
477

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Atenolol Pathway	SMP00298
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Carvedilol Pathway	SMP00367
Diltiazem Pathway	SMP00359
Esmolol Pathway	SMP00301
Labetalol Pathway	SMP00368
Metoprolol Pathway	SMP00302
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Beta-1 adrenergic receptor
MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG
MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV
WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC
TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP
LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV
FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP
PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity

# Drug_Target_1_SwissProt_ID:
P08588

# Drug_Target_1_SwissProt_Name:
ADRB1_HUMAN

# Drug_Target_1_Synonyms:
Beta-1 adrenoceptor
Beta-1 adrenoreceptor

# Drug_Target_1_Theoretical_pI:
9.03

# Drug_Target_1_Transmembrane_Regions:
60-83
97-120
132-155
176-199
222-245
326-349
357-380

#END_DRUGCARD DB00187
